Ads
related to: cannabinoid inverse agonists cream for skin
Search results
Results from the WOW.Com Content Network
Zevaquenabant was described as a third generation cannabinoid receptor 1 (CB1R) antagonist due to its peripheral selectivity and polypharmacology. [1] It acts as a peripherally selective inverse agonist of the cannabinoid receptor 1 and an inducible nitric oxide synthase (iNOS) inhibitor.
AM-251 is an inverse agonist at the CB 1 cannabinoid receptor. AM-251 is structurally very close to rimonabant; both are biarylpyrazole cannabinoid receptor antagonists.In AM-251, the p-chloro group attached to the phenyl substituent at C-5 of the pyrazole ring is replaced with a p-iodo group.
S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist. [1] It was developed as an antipruritic, and has moderate selectivity for the CB 2 subtype, having a CB 2 affinity of 18nM, and 32x selectivity over the CB 1 receptor.
Ibipinabant (SLV319, BMS-646,256) is a drug used in scientific research which acts as a potent and highly selective CB 1 antagonist. [1] It has potent anorectic effects in animals, [2] and was researched for the treatment of obesity, although CB 1 antagonists as a class have now fallen out of favour as potential anorectics following the problems seen with rimonabant, and so ibipinabant is now ...
Rimonabant is a selective CB 1 receptor blocker and was discovered and developed by Sanofi-Aventis. [6]On 21 June 2006, the European Commission approved the sale of rimonabant in the then-25-member European Union as a prescription drug for use in conjunction with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m 2, or patients with a BMI greater than 27 kg/m 2 ...
This fact led to the logical extension that blocking of the cannabinoid receptors might be useful in decreasing appetite and food intake. [11] It was then discovered that the blockage of the CB 1 receptor represented a new pharmacological target. The first specific CB 1 receptor antagonist / inverse agonist was rimonabant, discovered in 1994 ...
CID16020046 is a compound which acts as an inverse agonist at the former orphan receptor GPR55, [1] and may be the first selective inverse agonist characterised for this receptor. It was found to block a number of GPR55 mediated responses such as wound healing and activation of immune system T-cells and B-cells, as well as showing inverse ...
Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB 1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects. [1] [2] It was developed by Merck & Co.
Ads
related to: cannabinoid inverse agonists cream for skin